A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP
Tóm tắt
Oscillating positive expiratory pressure (OPEP) devices may reduce chronic symptoms in patients with obstructive pulmonary disease (COPD); however, no real-world studies have been performed to evaluate the benefits of these devices. The objective of this study was to measure the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients treated with Aerobika, an OPEP device, vs. a matched control group in a real-world setting. The study utilized data from the QuintilesIMS’ CDM hospital database. COPD patients treated with Aerobika OPEP between 9/2013 and 8/2015 were propensity score matched to COPD patients who did not use any positive expiratory pressure device. Severe exacerbation was defined as a hospital admission with a diagnosis for chronic bronchitis or COPD. Moderate-to-severe exacerbation was defined as a hospitalization or an ED visit with a diagnosis for chronic bronchitis or COPD. Exacerbations and costs were compared between cohorts at 30 days. A generalized linear model (GLM) was used to estimate the marginal effect of Aerobika OPEP on the cost of ED visits and hospitalizations due to COPD exacerbations. A total of 405 Aerobika OPEP patients were matched to 405 controls. At 30 days, 18.5% of subjects using the Aerobika OPEP vs. 25.7% of controls had a moderate-to-severe exacerbation (p = 0.014); 13.8% of subjects with Aerobika OPEP vs. 19.0% of controls had a severe exacerbation (p = 0.046). The mean per patient cost of moderate-to-severe exacerbations and severe exacerbations in the Aerobika OPEP group was significantly lower than controls ($2975 vs. $6065; p = 0.008, and $2838 vs. $5871; p = 0.009, respectively). In the GLM, the per-patient cost of moderate-to-severe exacerbations in the Aerobika OPEP group was 34% lower (p = 0.012) than the control group. Study findings suggest that using Aerobika OPEP as part of a treatment regimen may help reduce ED visits, hospital re-admissions and related costs in COPD patients who have a history of exacerbations.
Tài liệu tham khảo
Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23.
Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. J Cardiopulm Rehabil Prev. 2008;28(2):147–8.
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.
Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.
O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease–2007 update. Can Respir J. 2007;14(Suppl B):5B–32B.
Khakban A, Sin DD, FitzGerald JM, McManus B, Ng R, Hollander Z, Sadatsafavi M. The projected epidemic of COPD hospitalizations over the next 15 years: a population based perspective. Am J Respir Crit Care Med. 2016. [Epub ahead of print].
Shah T, Press VG, Huisingh-Scheetz M, et al. COPD readmissions: addressing COPD in the era of value-based healthcare. Chest. 2016. [Epub ahead of print].
O’Donnell DE, Parker CM. COPD exacerbations· 3: pathophysiology. Thorax. 2006;61(4):354–61.
Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003;10(Suppl B):3B–32B.
Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD J Chron Obst Pulm Dis. 2012;9(2):131–41.
Puhan MA, Scharplatz M, Troosters T, et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality–a systematic review. Respir Res. 2005;6(1):1.
From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD). 2017. http://goldcopd.org.
Svenningsen S, Paulin G, Wheatley A, Pike D, Suggett J, McCormack D, Parraga G. Oscillating positive expiratory pressure (oPEP) therapy in chronic obstructive pulmonary disease and bronchiectasis. Eur Respir J. 2014;44(Suppl 58):P3679.
Svenningsen S, Paulin GA, Sheikh K, Guo F, Hasany A, Kirby M, Etemad Rezai R, McCormack DG, Parraga G. Oscillatory positive expiratory pressure in chronic obstructive pulmonary disease. COPD J Chron Obstr Pulm Dis. 2016;13(1):66–74.
Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—part III. Value Health. 2009;12(8):1062–73.
Nazir SA, Erbland ML. Chronic obstructive pulmonary disease. Drugs Aging. 2009;26(10):813–31.
AbuDagga A, Sun SX, Tan H, Solem CT. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US-managed care population: an administrative claims data analysis. Int J Chron Obstr Pulmon Dis. 2013;8(1):175–85.
Cost H. Utilization project (HCUP). Overview of the nationwide inpatient sample, (NIS). http://www.hcup-us.ahrq.gov/databases.jsp. Accessed Feb 2009.
Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson Å, Prütz C, Rönmark E, Lundbäck B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96(9):700–8.
Trudell Medical International. Aerobika* oscillating positive expiratory pressure therapy system. Instructions for use. 2013. https://www.trudellmed.com/sites/trudellmed.com/files/pdf/consumer/opep_ifu.pdf. Accessed Jan 12, 2017.